Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 8,374 matching trials from the live ClinicalTrials.gov search.
Conditions
B-cell Non Hodgkin Lymphoma
Interventions
ARC-02, Rituximab
Drug
Lead sponsor
Taiho Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
7
States / cities
Los Angeles, California • Louisville, Kentucky • New York, New York + 4 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparison of Serum Contraceptive Hormone Levels Between Normal Weight and Obese Users of the NuvaRing®

NCT00710606
Conditions
Pharmacokinetics
Interventions
NuvaRing
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
New York, New York
Conditions
Diabetes
Interventions
Pioglitazone then Placebo, Placebo then Pioglitazone
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
40 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Malignant Glioma, Glioblastoma Multiforme, Gliosarcoma
Interventions
Gliadel/Avastin/CPT-11
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Immune-related Adverse Events, Advanced Solid Tumor
Interventions
Rituximab, Tocilizumab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Baltimore, Maryland • New York, New York
Conditions
SCC - Squamous Cell Carcinoma, Radiotracer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Carcinoma
Interventions
Cetuximab (EGFR inhibitor), 18F-NOTA-ABY-030, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Solid Tumors, NHL
Interventions
KPT-9274, Niacin ER, Nivolumab
Drug
Lead sponsor
Karyopharm Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Conditions
Non-Hodgkin's Lymphoma
Interventions
bortezomib, bendamustine, rituximab
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
Omaha, Nebraska • New York, New York • Rochester, New York
Conditions
Advanced Solid Tumor
Interventions
Ramucirumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Fayetteville, Arkansas • Omaha, Nebraska • Charlotte, North Carolina + 1 more
Conditions
AIDS-Related-Primary Central Nervous System Lymphoma
Interventions
Methotrexate, Rituximab, Leucovorin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
HIV Infections
Interventions
Anti-HIV Immune Serum Globulin (Human)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
Non Hodgkin Lymphoma
Interventions
acalabrutinib, rituximab (IV), Lenalidomide
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
23
States / cities
Tucson, Arizona • Downey, California • Duarte, California + 18 more
Completed Not applicable Interventional Results available

Phenytoin and Multidose Activated Charcoal

NCT00823264
Conditions
Phenytoin Toxicity
Interventions
Activated Charcoal
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Relapsed/Refractory Primary Central Nervous System Lymphoma
Interventions
Tirabrutinib, Rituximab, Temozolomide
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fullerton, California + 18 more
Conditions
Neurofibromatosis Type 2, Progressive Vestibular Schwannomas
Interventions
Bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
6 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
12
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 9 more
Conditions
HER2-positive Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions
lapatinib ditosylate, paclitaxel, trastuzumab, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
Drug · Biological · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
20 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hyperparathyroidism, Primary, Hypercalcemia
Interventions
Cinacalcet, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
22
States / cities
Lake Forest, California • Lancaster, California • Los Gatos, California + 19 more
Conditions
Uveitis
Interventions
Daclizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Previously-Irradiated, Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions
SBRT, Cetuximab, Docetaxel
Radiation · Drug
Lead sponsor
Heath Skinner
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Brain and Central Nervous System Tumors
Interventions
bevacizumab, irinotecan, dynamic contrast-enhanced magnetic resonance imaging
Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Locally Advanced Cancer, Metastatic Cancer
Interventions
OMP-313M32, Nivolumab
Drug
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
Scottsdale, Arizona • Durham, North Carolina • Oklahoma City, Oklahoma + 2 more
Conditions
Lymphoma
Interventions
rituximab, yttrium Y 90 ibritumomab tiuxetan
Biological · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Cancers
Interventions
HAI Abraxane, Gemcitabine, Bevacizumab, Filgrastim
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pancreatic Cancer Stage IV
Interventions
Gemcitabine, Nivolumab 10 MG/ML Intravenous Solution [OPDIVO], Cabiralizumab
Drug
Lead sponsor
Hitendra Patel
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
La Jolla, California